Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 383 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Primary Pulmonary Hypertension Clear all

Conditions: Primary Pulmonary Hypertension
Interventions: LIQ861 Inhaled Treprostinil; Drug
Lead sponsor: Liquidia Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 38
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 30 more

Conditions: Pulmonary Arterial Hypertension
Interventions: GB002 (seralutinib), Generic Dry Powder Inhaler; Drug · Device
Lead sponsor: Gossamer Bio USA, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 15
States / cities: Sacramento, California • Santa Barbara, California • Jacksonville, Florida + 11 more

Conditions: Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: Franz Rischard, DO; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Pulmonary Arterial Hypertension
Interventions: Ambrisentan, Placebo, Sildenafil, Tadalafil; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 30
States / cities: Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Birmingham, Alabama • Torrance, California • Jacksonville, Florida

Conditions: Pulmonary Arterial Hypertension
Interventions: Fluoxetine; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 16 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pulmonary Arterial Hypertension
Interventions: PAH Therapies; Other
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 15
States / cities: Brandon, Florida • Tampa, Florida • Chicago, Illinois + 12 more

Conditions: Interstitial Lung Disease, COPD, Cystic Fibrosis, Pulmonary Fibrosis, Pulmonary Arterial Hypertension, Emphysema
Interventions: LungGuard, BAROGuard; Device
Lead sponsor: Paragonix Technologies; Industry
Eligibility: Not listed
Enrollment: 3,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 14
States / cities: Phoenix, Arizona • San Francisco, California • Stanford, California + 10 more

Conditions: Pulmonary Hypertension
Interventions: Oral treprostinil (UT-15C) Sustained Release Tablets, Placebo; Drug · Other
Lead sponsor: United Therapeutics; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 43
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more

Conditions: PAH
Interventions: 75mg CXA-10, 150mg CXA-10, Placebo; Drug · Other
Lead sponsor: Complexa, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more

Conditions: Pulmonary Artery Hypertension
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypertension, Pulmonary
Interventions: ambrisentan, tadalafil; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 61
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 50 more

Conditions: PAH
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 8
States / cities: Aurora, Colorado • Weston, Florida • Baltimore, Maryland + 5 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Sotatercept, Background PAH Therapy; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 9
States / cities: Phoenix, Arizona • Aurora, Colorado • Indianapolis, Indiana + 6 more

Conditions: Heart Failure, Pulmonary Arterial Hypertension
Interventions: right heart catheterization; Diagnostic Test
Lead sponsor: Silverleaf Medical Sciences INC; Industry
Eligibility: 20 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Sarcoidosis, Pulmonary Arterial Hypertension
Interventions: Bosentan, Placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 4
States / cities: New York, New York • Cincinnati, Ohio • Cleveland, Ohio + 1 more

Conditions: Healthy
Interventions: Rodatristat Ethyl 300 mg BID, Rodatristat Ethyl 600 mg BID, Placebo; Drug
Lead sponsor: Altavant Sciences GmbH; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Pulmonary Arterial Hypertension
Interventions: 18F-FGLN PET Imaging, (18F)FPGLU; Diagnostic Test · Drug
Lead sponsor: Stephen Y. Chan; Other
Eligibility: 18 Years to 75 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pulmonary Arterial Hypertension
Interventions: Riociguat (Adempas, BAY63-2521); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 49
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 38 more

Conditions: Pulmonary Arterial Hypertension
Interventions: JNJ-67896049; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: La Jolla, California • Anderson, South Carolina • Dallas, Texas

Conditions: Pulmonary Arterial Hypertension
Interventions: Elafin, Placebo; Drug
Lead sponsor: Roham T. Zamanian; Other
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension
Interventions: Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, BQ-123, MitoQ, BH4; Other · Drug
Lead sponsor: D. Walter Wray; Other
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2030
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pulmonary Arterial Hypertension
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pulmonary Hypertension
Interventions: Ultrasound Doppler; Radiation
Lead sponsor: Echosense Ltd.; Industry
Eligibility: Not listed
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2021
U.S. locations: 2
States / cities: Palo Alto, California

Search by objective public record fields.

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

Reverse Remodeling of the Pulmonary Vasculature: a Longitudinal, Investigational Study of the Effects of Sotatercept.

Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)

Sildenafil to Tadalafil in Pulmonary Arterial Hypertension (SITAR)

Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension

A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants

Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs

FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)

Vascular Subphenotypes of Lung Disease in HIV & COPD

A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

Pulmonary Hypertension and Imatinib

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)

Non-invasive Pulmonary Artery Prediction (ADOPTS)

Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension

Multiple-Ascending Dose in Japanese Patients Bridging Study

PET Image in PAH Patients

A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)

A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging

Subcutaneous Elafin in Healthy Subjects

: Vascular Function in Health and Disease

Effects of Pulmonary Hypertension Therapy in Atypical Pulmonary Arterial Hypertension

Measurements and Characterization of Doppler Signals From the Right Chest in Pediatric and Adult Patients